Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang luzetutazumab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The drug is intended for treatment with bevacizumab in patients with locally advanced EGFR mutations or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously failed to be treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).
Zhitongcaijing · 2d ago
Share
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang luzetutazumab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The drug is intended for treatment with bevacizumab in patients with locally advanced EGFR mutations or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously failed to be treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending